Galera Therapeutics to merge with Obsidian in all-stock deal backed by $350M PIPE

Galera Therapeutics, Inc.

Galera and Obsidian to merge under new parent; Galera shareholders get ~1.8% of combined co plus CVRs.
Obsidian shareholders get ~53.2%; $350M PIPE investors get ~45% of combined company.
Galera valued at $13.8M (net cash $1.8M), Obsidian at $413.5M; closing conditions include S-4 effectiveness.
Galera legacy assets (tilarganine, avasopasem, rucosopasem) subject to CVR payout to Galera common holders.
Insider support: 51.1% Galera holders and 62.8% Obsidian holders agree to vote in favor.

item 1.01 item 3.02 item 5.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Galera Therapeutics, Inc. entered into Agreement and Plan of Merger with Obsidian Therapeutics, Inc., Gazelle Parent, Inc., Onyx MergerSub, Inc., Gazelle Merger Subsidiary, Inc. (effective 2026-04-14).

Action: entry
Agreement: merger
Counterparty: Obsidian Therapeutics, Inc., Gazelle Parent, Inc., Onyx MergerSub, Inc., Gazelle Merger Subsidiary, Inc.
Effective: 2026-04-14

Exact text from the filing

On April 14, 2026, Galera Therapeutics, Inc., a Delaware corporation (“Galera”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Galera, Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”), Gazelle Parent, Inc., a Delaware corporation (“Parent”), Onyx MergerSub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Obsidian Merger Sub”), and Gazelle Merger Subsidiary, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Galera Merger Sub”).

View on SEC.gov

Browse all material agreements →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-154009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.